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ABSTRACT
Mitochondrial DNA (mtDNA) is entirely dependent on
nuclear genes for its transcription and replication.
One of these genes is TOP1MT, which encodes
the mitochondrial DNA topoisomerase IB, involved
in mtDNA relaxation. To elucidate TOP1MT regula-
tion, we performed genome-wide profiling across
the 60-cell line panel (the NCI-60) of the National
Cancer Institute Developmental Therapeutics
Program. We show that TOP1MT mRNA expression
varies widely across these cell lines with the highest
levels in leukemia (HL-60, K-562) and melanoma
(SK-MEL-28), intermediate levels in breast
(MDA-MB-231), ovarian (OVCAR) and colon
(HCT-116, HCT-15, KM-12), and lowest levels in
renal (ACHN, A498), prostate (PC-3, DU-145) and
central nervous system cell lines (SF-539, SF-268,
SF-295). Genome-wide analyses show that TOP1MT
expression is significantly correlated with the other
mitochondrial nuclear-encoded genes including
the mitochondrial nucleoid genes, and demonstrate
an overall co-regulation of the mitochondrial
nuclear-encoded genes. We also find very high cor-
relation between the expression of TOP1MT and the
proto-oncogene MYC (c-myc). TOP1MT contains
E-boxes (c-myc binding sites) and TOP1MT tran-
scription follows MYC up- and down-regulation by
MYC promoter activation and siRNA against MYC.
Our finding implicates MYC as a novel regulator of
TOP1MT and confirms its role as a master regulator
of MNEGs and mitochondrial nucleoids.
INTRODUCTION
Mitochondria are the intracellular organelles responsible
for most of the ATP production in eukaryotic cells (1,2).
They are essential in several metabolic processes including
the urea and Krebs cycles, b-oxidation, the synthesis
of heme, pyrimidines and other metabolites (1).
Mitochondria also control cell survival by virtue of their
key role in the intrinsic apoptosis pathway cascade (3).
Over the past few years, mitochondrial defects have been
linked to neurodegenerative (Alzheimer and Parkinson)
and metabolic (diabetes, obesity) diseases and cancers
(1,2). Mitochondrial DNA (mtDNA) mutations and poly-
morphisms, and mitochondrial pathway dysregulations
are being found in cancer cells (1,2).
Although the human mtDNA encodes 13 of the essen-
tial proteins for the respiratory chain, the vast majority
(>1000) (4) of the mitochondrial proteome is encoded in
the cell nucleus (5). The mitochondrial nuclear-encoded
genes (MNEGs for short) comprise all the genes needed
for mtDNA replication, translation, scaffolding and struc-
tural maintenance (1,6–8). One of the MNEGs is the mito-
chondrial topoisomerase I (TOP1MT) gene, which
encodes an enzyme exclusively targeted to mitochondria
(9–12). TOP1MT resolves the mtDNA supercoiling result-
ing from mtDNA transcription and replication within
mitochondrial nucleoids (8,13–15). Mitochondrial
nucleoids are clusters of 5–10 mtDNA molecules highly
compacted as nucleoprotein complexes anchored together
to the mitochondrial inner membrane (13).
Approximately, 60 different proteins have been identiﬁed
within nucleoids, with 31 of them classiﬁed as core
nucleoid proteins, including TOP1MT, TFAM,
single-stranded DNA binding protein 1 (SSBP1), DNA
polymerase and helicases (like Twinkle—C10orf2) and
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tebrates, and is highly similar to nuclear TOP1, with the
exception of having a unique mitochondrial localization
signal peptide at its N-terminus (10,16). TOP1MT is a
type IB topoisomerase; i.e. it produces reversible
single-stranded DNA breaks by covalently linking to the
30-end of the DNA breaks that it generates to relax
DNA supercoiling (16–18). Recently, TOP1MT muta-
tions have been identiﬁed in patients affected by mito-
chondrial disorders suggesting a new role for
this enzyme in the pathogenesis of mitochondrial
diseases (19).
Increasing evidence supports extensive cross-talk
between mitochondria and the nucleus to coordinate mito-
chondrial biogenesis and replication with the overall
cellular metabolism. Several transcription factors and
nuclear co-activators have been involved (20). Among
them, NRF1, GABPA (also known as NRF-2), PPARA
(21), ESRRA and SP1 plays a major role in
nuclear-mitochondrial interactions, as do members of
the PGC-1 family (PPARGC1A, PPARGC1B and
PPRC1) that drive MNEG transcription through their ac-
tivation by environmental stimuli, such as nutrient abun-
dance, cell starvation, growth factors and temperature
(20). Recently, the helix–loop–helix/leucine-zipper tran-
scription factor and proto-oncogene c-myc (22), encoded
by MYC has been associated with mitochondrial biogen-
esis and proliferation (23–30), raising the possibility that
the control of the mitochondrial machinery is among the
multiple functions of MYC, together with cellular prolif-
eration, progression of cell cycle, apoptosis and cellular
transformation (20,31).
To study large-scale genomics, a suitable model is the
cancer cell line collection of the National Cancer Institute
Developmental Therapeutics Program (NCI-DTP),
known as the NCI-60 panel (32,33). This panel includes
60 cell lines from nine different tissues of origin (breast,
central nervous system, leukemia, colon, lung, melanoma,
ovary, prostate and kidney). The NCI-60 cancer cell lines
have been tested over time against more than 400000 com-
pounds, including synthetic and natural products as well
as anticancer agents (32,33). The NCI-60 are also one of
the best characterized cell line collections for mRNA ex-
pression across multiple microarray platforms (34,35),
microRNA expression (36), chromosomal aberrations
(37), DNA copy number (38) and protein proﬁling
(39,40). The NCI-60 cell panel and associated databases
provide a powerful approach to discover the biological
features of novel genes, and to better understand the re-
lationship of such genes with other functional genomic
pathways. The NCI-60, with their thorough characteriza-
tion obtained by several, independent high-throughput
techniques, are therefore a unique approach to study
gene expression, alterations and correlations, which
could be especially useful for poorly understood and rela-
tively novel genes, and their relationship in cellular mo-
lecular networks.
Here, we made use of genome-wide expression analysis
performed on the NCI-60 to shed light on the genomic
determinants of TOP1MT expression.
MATERIALS AND METHODS
Cell lines
The NCI-60 panel of cancer cell lines used for microarray
analysis was obtained from the NCI DTP. For the MYC
silencing experiment, MCF7 cells (American Type Culture
Collection, Manassas, VA, USA) were cultivated in
DMEM medium supplemented with 10% fetal calf
serum. MYC inducible MCF7-PJMMR1 cells were
kindly provided by Dr H. Hermeking and maintained in
DMEM medium supplemented with 10% fetal calf serum
as described previously (41). Doxycycline (Sigma
Chemical Co., St Louis, MO, USA) was dissolved in
water (20mg/ml stock solution) and used at a ﬁnal con-
centration of 1mg/ml.
Gene nomenclature
All gene names reported in this article are in accordance
with the HUGO Gene Nomenclature Committee (http://
www.genenames.org).
mRNA processing and microarray analysis
mRNA extraction, puriﬁcation, quality control, micro-
array hybridization, proﬁling and quality assessment
have been described previously (36). In brief, after extrac-
tion with the RNeasy puriﬁcation kit (Qiagen Inc.) and
quality control (2100 Expert_Eukaryotic Total RNA Pico
assay, Agilent Technologies, Santa Clara, CA, USA),
200ng of mRNA from each cancer cell line sample were
labeled and processed following the Agilent Technologies
One-Color Microarray-Based Gene Expression Analysis
Protocol version 5.5. All experiments were performed in
duplicate, with the exception of breast cancer cell line
MCF7, colorectal HCT116 and HT29, leukemia K562,
melanoma SK-MEL-2 and renal CAKl-1, which were
assayed in quadruplicate. All 132 labeled samples were
hybridized to the Agilent Whole Human Genome Oligo
Microarray (WHG; G4112F, design ID 014850, Agilent
Technologies, Santa Clara, CA, USA), containing 41000
probes (22144 unique gene IDs). After scanning and data
extraction with Feature Extraction (version 9.5, Agilent
Technologies, Santa Clara, CA, USA), data quality was
veriﬁed using the Agilent quality control metrics. The
described microarray dataset is available at GEO
website (accession number GSE22821).
Quantitation of gene transcript expression using ﬁve
microarray platforms
Transcript expression data from TOP1MT, MYC and the
other topoisomerases were obtained from ﬁve microarray
platforms that have been exploited to generate transcrip-
tome values in the NCI-60: Affymetrix Human Genome
U95 (HG-U95; approximately 60000 features; Affymetrix
Inc.), Human Genome U133 (HG-U133a and b; approxi-
mately 44000 features), Human Genome U133 Plus 2.0
(HG-U133 Plus 2.0; approximately 47000 features),
Agilent WHG, and Affymetrix GeneChip Human Exon
1.0 ST (GH Exon 1.0 ST; approximately 850000
features). GC robust multi-array average (GCRMA) was
used to normalize HG-U133 and HG-U95 arrays, whereas
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normalization. Further details on mRNA processing and
microarray analysis for the aforementioned data sets have
been described elsewhere (42). To generate gene transcript
expression values, non-degenerate probes [as determined
by SpliceCenter (http://www.tigerteamconsulting.com/
SpliceCenter/SpliceOverview.jsp)] from the ﬁve platforms
with an intensity range of  1.2 log2 and with a Pearson’s
correlation coefﬁcient with other probes  0.60 were used.
Probes passing these quality criteria were used to deter-
mine a z-score value for gene transcript intensities as
follows: each probe intensity value was subtracted by the
mean for that probe across all samples, and divided by its
standard deviation. z-scores were then averaged to
generate a consensus gene transcription proﬁle across all
the ﬁve platforms used for such analysis.
MNEG database
For MNEG transcript analysis, we used the MitoCarta
human inventory (4). MitoCarta is a collection of 1013
nuclear and mtDNA genes-encoding proteins with
strong support of mitochondrial localization based on
homology to mouse MitoCarta genes.
Pathway analysis
Data were analyzed for pathway enrichment with
MetaCore software from GeneGo (GeneGo Inc., St
Joseph, MI, USA). Oncomine
TM (Compendia
Bioscience, Ann Arbor, MI, USA) was used for analysis
and visualization of TOP1MT co-expressed genes in
multiple independent cancer microarray databases.
Array CGH analysis
For array CGH analysis, samples from the NCI-60 were
prepared and analyzed with NimbleGen 385K aCGH
chips (NimbleGen HG18 CGH 385K WG Tiling v2.0;
NimbleGen Systems, Inc., Madison, WI, USA) according
to Manufacturer’s speciﬁcations (http://www.nimblegen
.com/products/lit/cgh_userguide_v6p0.pdf). The experi-
ment did not include the HT29 cell line. In brief, 1.5mg
of genomic DNA from cancer cell lines and from human
male reference samples were puriﬁed, labeled using
Cy3-Random and Cy5-Random Nonamers, respectively,
and hybridized to NimbleGen arrays. NimbleGen pairs
ﬁles were loaded in Partek Genomics Suite 6.4 (Partek
Inc., St Louis, MO, USA). Approximate copy numbers
for MYC and TOP1MT genes were obtained from
the average of intensities of the probes located inside
MYC (8:128817497:128822855) and TOP1MT
(8:144391526:144417050) locations, and the seven probes
on their p and q termini, as follows:
N ¼ C   Lintensity ¼ 2   2intensity,
where N is DNA copy number for the analyzed gene, C is
the correction for generating the intensities as a ratio of
the cell lines intensity to a normal, 2N, DNA=2, and
L=log of the intensity value=2.
Statistical analyses
Analysis of Agilent output text ﬁles was performed with
Agilent GeneSpring GX 10.0 (Agilent Technologies Inc.,
Santa Clara, CA, USA), while Affymetrix CEL ﬁles and
NimbleGen pairs ﬁles were analyzed using Partek
software (Partek Inc., St Louis, MO, USA). Data were
then loaded into R for further analysis (http://www.R-
project.org). Pearson product moment correlation was
used to infer genes co-expressed with TOP1MT and
MYC transcripts, using the data from Agilent WHG
chips. Proportions of MNEGs in TOP1MT and MYC
correlating genes were compared to those in
non-correlating ones with the  
2-test. Clustered image
maps (CIMs for short) were generated with the
CIMminer tool, freely available in our Genomics and
Bioinformatics Group website (http://discover.nci.nih
.gov/). Euclidean distance method was used for gene
expression CIMs and for gene correlation (square
matrix) CIMs. The clustering method was average
linkage for both types of CIM. In pathway analyses
with MetaCore, processes and pathways were con-
sidered signiﬁcantly enriched when having a P<0.01,
as calculated by hypergeometric distribution.
Distribution plots for gene expression and gene correl-
ations were generated by Gaussian kernel density estima-
tion. Student’s t-test was used to compare variable
means of the different experimental groups in MYC
silencing and induction experiments. The a posteriori
probability of the correlation between TOP1MT and
nucleoid genes was calculated using a Bayesian
approach, assuming an a priory positive correlation
between TOP1MT and MNEGS equal to the experimen-
tally determined value of 16.7%. All P-values are
from two-tailed tests. R was used for statistical analysis
and for graphics generation. R and the package
permtest, with minor script modiﬁcations, were used for
bootstrap comparison of the Euclidean distance within
MNEGs and randomly generated gene sets of the
same dimension. Figures were ﬁnalized with Adobe
Design Suit Standard CS3.
Short-interfering RNA
MYC-targeting short interfering (siRNA) (validated
siRNA, catalog number SI00300902) and non-silencing
control siRNA (AllStars Negative Control siRNA,
catalog number 1027280) were obtained from Qiagen
(Valencia, CA, USA). Cells were seeded in 6-well plates,
at a density of 200000 cells per well, 16h before transfec-
tion. For each sample, 125nM of siRNA was mixed with
250ml of Opti-MEM (mixture A; Invitrogen, Carlsbad,
CA). Five microliter of Lipofectamine 2000 (Invitrogen)
were mixed with 250ml of Opti-MEM and incubated for
5min at room temperature (mixture B). After mixing
(mixtures A and B) and further incubation for 20min at
room temperature, the siRNA/Lipofectamine complexes
were added to 2ml of culture medium. After 5h, the
medium was replaced with regular medium and the cells
were incubated for 72h.
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Total RNA was isolated from 1 10
6cells using RNeasy
Mini Kit (Qiagen). An aliquot of 1mg RNA was reverse
transcribed using a reverse transcription kit (Promega,
Madison, WI, USA). Real-time PCR was performed
with the SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) on the ABI 7900
thermocycler (Applied Biosystems). Expression level of
MYC and TFAM were normalized by b2-microglobulin
RNA level of the same sample. Reaction mixtures con-
tained 5mlo f2   Quantitect SYBR-Green PCR Master
Mix (Applied Biosystems), 2ml of reverse
transcriptase-generated cDNA diluted by 100 in a ﬁnal
volume of 10ml containing primers purchased from
IDT-DNA Inc. (Coralville, IA, USA) at 125nM.
Relative gene expression was expressed as a ratio of the
expression level of the gene of interest to that of
b2-microglobulin RNA, with values in non-transfected
cells deﬁned as 100%. Primer sequences are available as
Supplementary Data.
RESULTS
Mitochondrial topoisomerase (TOP1MT) has a wide
expression range across the NCI-60
We analyzed TOP1MT transcript expression in the
NCI-60 panel of cancer cell lines by microarray, using
Agilent WHG chips (36). The reproducibility of
TOP1MT intensities measures was evaluated by
comparing its transcriptional proﬁle from the Agilent
WHG chips with the data from four different micro-
array platforms exploited in previous gene-expression
studies of the NCI-60 (http://discover.nci.nih.gov/
cellminer/) (Affymetrix HG-U95, HG-U133 a-b,
HG-U133 Plus 2.0, Human Exon 1.0 ST) (42,43).
Results were highly concordant across the ﬁve platforms,
yielding a total of 17 highly correlating probes for
TOP1MT, which demonstrates the high reproducibility
and accuracy of transcript analyses in the NCI-60 data-
bases (36).
TOP1MT was expressed in all cell lines with a broad
expression range (Figure 1). TOP1MT transcript intensity
in all the 60 cell lines was above the 75th percentile of gene
expression across all probes found in the Agilent WHG
chips, indicating that all the 60 cell lines express TOP1MT
transcript at an  8-fold variable level of difference
between the lowest and the highest TOP1MT expressing
cell lines (Supplementary Figure S1A and B). Notably, all
cell lines of hematological origin (acute lymphoblastic
leukemia CCRF-CEM and MOLT-4, lymphoma SR,
promyelocytic leukemia HL-60, multiple myeloma
RPMI-8226 and chronic myelogenous leukemia K-562)
and 5 out of 10 melanoma lines (SK-MEL-288,
SK-MEL-2, M14, MALME-3M and LOXIMVI) showed
relatively high TOP1MT expression, whereas cancer cell
lines of central nervous system (SNB-75, SNB-19, SF-539,
U251, SF-295 and SF-268) and lung origin (NC-H460,
NCI-H226, HOP-62 and EKVX) were among the lowest
expressers for TOP1MT.
TOP1MT shows a unique pattern of expression across
the NCI-60 compared to the other topoisomerases
Correlation analysis of TOP1MT expression with the
other ﬁve human topoisomerase genes indicated a broad
range of expression of all six genes across the NCI-60
(Supplementary Figure S1A and B and Supplementary
Spreadsheet S1). TOP1MT showed a weak but signiﬁcant
correlation with the nuclear type IB topoisomerase
(TOP1) (0.28, P<0.05) and a signiﬁcant negative correl-
ation with TOP2A ( 0.36, P<0.01) (Supplementary
Figure S1C). No signiﬁcant correlation was found
between TOP1MT and TOP2B, TOP3A or TOP3B.
Overall, the differential expression patterns among the
six topoisomerase genes reﬂect their independent regula-
tion and complementary functions.
TOP1MT is co-expressed with other MNEGs
Next we compared the expression proﬁle of TOP1MT
with that of 978 MNEGs derived from the MitoCarta
database. Figure 2A demonstrates a signiﬁcant positive
correlation of TOP1MT with 163 MNEGs (from 216
probes). Of interest, a notably strong bias was found for
positive correlations (163 positively correlating versus
12 negatively correlating genes, P<0.0001). Moreover,
the proportion of MNEGs that correlated positively
with TOP1MT was also higher than the positively
correlating non-mitochondrial genes (16.7%, 163 out of
978 MNEGs, compared with 9.1%, 1917 out of 18173
non-mitochondrial genes, P<0.0001; Figure 2C and D).
Together, these results demonstrate the overall co-
expression of the MNEGs including TOP1MT.
Within the group of MNEGs that correlate positively
with TOP1MT, several encode known components of the
mitochondrial nucleoids (8,13,14,44–48) (Figure 2B), sug-
gesting that TOP1MT is co-regulated with genes that are
essential for mtDNA scaffolding and organization.
Among the core nucleoid genes with quality-passing
values (n=42), TOP1MT correlates (P<0.05 or less;
two-sided Pearson’s correlation coefﬁcient) with 9 out of
11 mitochondrial metabolism genes, all 5 DNA scaffold
genes and 5 out of 7 RNA metabolism nucleoid genes
(Supplementary Table S2). Generally, TOP1MT correl-
ates signiﬁcantly with 64% of the nucleoid genes with an
available value. In particular, among those nucleoid genes
positively correlating with TOP1MT, are both subunits of
polymerase g (POLG and POLG2), the helicase Twinkle
(C10orf2), the mitochondrial RNA polymerase
(POLRMT), ATAD3A and ATAD3B, the mitochondrial
transcription factors A, B1 and B2 (TFAM, TFB1M and
TFB2M), and the SSBP1. Together, these results demon-
strate the co-regulation of the mitochondrial nucleoid
genes (including TOP1MT).
Clustering of the MNEGs reveals co-regulated functional
gene subsets, and highlights biological differences in
mitochondrial regulation across the NCI-60
To further determine whether the MNEGs formed groups
based on their co-expression, we clustered the 978
MNEGs, corresponding to 1618 probes (mean probe
Nucleic Acids Research, 2011,Vol.39, No. 15 6623Figure 1. TOP1MT has a wide expression range in the NCI-60 panel. (A) TOP1MT mRNA expression intensity across the cell line panel from the
NCI (NCI-60), ranked from the highest TOP1MT expresser (leukemia RPMI-8226, top) to the lowest (lung NCI-H226, bottom). Tissues of origin
are designated by colored circles (see legend below). Names of the individual cell lines are reported. Expression values were obtained with Agilent
Whole Human Genome Oligo Microarray chips, and quality ﬁltering and normalization were performed using GeneSpring GX 10.0 software
(Agilent, Santa Clara, CA, USA). A value of one corresponds to a 2-fold higher intensity than the 75th percentile of expression for all probes
on the entire array. Values are on a log2 scale. (B) Normalized TOP1MT mRNA expressions sorted by level (highest to lowest) across the NCI-60.
Individual cell lines (ﬁlled dots) are colored according to tissue of origin and arranged by the intensity values in panel A. Inset: frequency distribution
plot showing the number of cell lines from the NCI-60 panel by TOP1MT normalized intensity. x-axis, normalized TOP1MT intensity; y-axis,
frequency of cell lines for any given TOP1MT intensity in the x-axis.
6624 Nucleic Acids Research, 2011,Vol.39, No. 15number for each gene 1.65, range 1–6), according to their
expression proﬁles in the NCI-60 (Figure 3A and B). Such
clustering reveals that MNEGs can be divided into several
groups (clusters) according to their co-expression
intensities. Gene ontology analysis revealed that each
cluster tends to be enriched in genes with coherent
biological functions. Highly expressed genes are related
to oxidative phosphorylation, ubiquinone metabolism,
DNA replication and translation, and mtDNA scaffolding
and structural maintenance (P<0.01 or less by
hypergeometric distribution test). On the other hand,
genes with low expression are more frequently involved
Figure 2. Co-expression of mitochondrial nuclear-encoded gene (MNEG) transcripts with TOP1MT across the NCI-60. (A) Waterfall plot showing
Pearson’s coefﬁcients for correlation between TOP1MT transcript intensity in the NCI-60 and the intensities of all MNEGs from the Human
MitoCarta Database, for which quality-ﬁltered probe intensities were found in the Agilent WHG platform for the NCI-60. Pearson’s correlation
coefﬁcients are sorted from highest positive (top) to lowest negative (bottom). Color codes are as follows: red=Pearson’s>0.330 (163 genes,
two-tailed P<0.01), orange=Pearson’s r>0.254 (290 genes, two-tailed P<0.05), turquoise=non-signiﬁcant correlations, light blue=Pearson’s
r< 0.254 (39 genes, two-tailed P<0.05), dark blue=Pearson’s r< 0.330 (12 genes, two-tailed P<0.01). (B) Mitochondrial nucleoid genes
correlating with TOP1MT. Functional groups are highlighted with different colors. (C) Density plot showing the distribution of Pearson’s correl-
ations of MNEGs (red) and all genes (blue) with TOP1MT. MNEGs show a signiﬁcant shift toward the right, indicating an excess of positive
correlations with TOP1MT as compared with the overall genome (P<0.0001, two-tailed unpaired t-test). Y-axis: density estimated values using a
Gaussian kernel. (D) Contingency table showing numbers and percents of MNEGs or non-mitochondrial genes that correlate positively, negatively or
do not correlate with TOP1MT.
Nucleic Acids Research, 2011,Vol.39, No. 15 6625in amino acid and nitrogen metabolism, fatty acid metab-
olism and transport of divalent metal ions (P<0.01 or
less) (Figure 3B).
The MNEGs showed less variation than the
non-mitochondrial genes across the NCI-60, as assessed
by comparing the standard deviations of the genes in these
two sets (P<0.0001 and Supplementary Figure S2A),
which suggests that all cancer cell lines may need relatively
steady expression of MNEGs.
Further analysis of the MNEG expression signatures
shows tissue-speciﬁc differences among the NCI-60.
Figure 3A shows that all 10 melanoma, 5 out of the 6
CNS, 6 out of the 7 colorectal, 7 out of the 9 lung, 6
out of the 8 renal and 4 out of the 6 leukemia cell lines
cluster together based on MNEG expressions. The clus-
tering of cell lines from the same tissues of origin suggests
the cancer cell lines have retained tissue of origin identities
(36), which impact on MNEGs expression as a function of
tissue of origin speciﬁcity.
To further analyze the co-regulation patterns of the
MNEGs, we generated a matrix of all pair-wise
Pearson’s correlations between MNEGs, and clustered
the square matrix along both axes. The resulting cluster
image map (CIM; Figure 3C) clusters genes according to
similarity (assessed by Euclidean distance) of their correl-
ation proﬁles, with the expected diagonal axis of
self-correlations of each gene to itself. This analysis
allows an immediate visual perception of large or small
clusters (uniformly colored squares in the CIM) that
include tightly co-expressed genes. Figure 3C demon-
strates the existence of four main clusters. The large
Cluster 1 is highly enriched in genes participating in mito-
chondrial translation (further detailed in Supplementary
Figure S3), oxidative phosphorylation, protein folding
and structural mitochondrial components. Notably,
TOP1MT, which is part of the highly expressed genes
(Cluster III of Figure 3B) clusters together with genes
involved in mitochondrial scaffolding, translation and oxi-
dative phosphorylation (Cluster 1 of Figure 3C). The
other smaller clusters in Figure 3C show the co-expression
of genes involved in apoptosis (Cluster 3), alcohol and
amino acid metabolism, and proteolysis (Cluster 4). Of
interest, the comparison of Euclidean distances within
the 1618 MNEG-hybridizing probes and 100 randomly
generated sets of the same dimension demonstrates that
the MNEGs behave as a coherent group, having a signiﬁ-
cantly smaller internal Euclidean distance than any
random group of genes (P<0.01, Supplementary
Figure S2B). Thus, our results demonstrate that the
MNEGs are highly co-regulated in the NCI-60.
MYC expression shows a signiﬁcant positive correlation
with TOP1MT and other MNEGs
We next looked for non-mitochondrial genes that correl-
ate with TOP1MT expression across the NCI-60. MYC
came up as the third highest positively correlated gene
(Pearson’s correlation coefﬁcient of 0.628 with TOP1MT
in the Agilent WHG chips) out of 5930 genes with a
Pearson’s coefﬁcient  0.254 (Supplementary
Figure S4A). The ﬁrst and second most highly correlated
genes are TFAP4 and TAF4B. TFAP4 is the transcription
factor AP-4, and TAF4B is the TATA box, RNA-Pol II
binding factor. Both genes have recently been shown to be
direct transcriptional targets of MYC (41,49), which puts
MYC and two MYC-related genes at the top of the genes
whose expression is most highly correlated with
TOP1MT.
MYC also correlates positively with 15.7% of the
MNEGs, whereas only 1.9% of the MNEGs correlate
negatively with MYC (Supplementary Figure S4B)
(P<0.0001 and Supplementary Figure S4D). Such
positive correlation was greater in proportion than the
correlation of MYC with non-mitochondrial genes
(15.7% versus 12.6%, P<0.05; Supplementary
Figure S4C and D). Analysis of an unpublished, publicly
available set of 318 cancer cell lines with Oncomine-4.3
independently validated the strong positive correlation
between TOP1MT and MYC transcripts (Supplementary
Figure S5).
The proﬁles of expression of MYC and TOP1MT
generated by normalizing all the microarray platform
results with the z-score transformation (42) are shown in
Figure 4. Overall, MYC and TOP1MT show signiﬁcant
correlation in their expression proﬁles across the NCI-60
(r=0.55; P<0.0001), with leukemia being the highest
TOP1MT and MYC co-expressers, and cell lines of
central nervous system origin being the lowest TOP1MT
and MYC expressers.
Array CGH analysis of the 2Mb region up- and down-
stream of the MYC locus demonstrated that cancer cell
lines with MYC ampliﬁcations also tended to have a
higher MYC transcript intensity when compared with
cells of the same tissue of origin without such alterations.
In particular, three cell lines (leukemia HL-60, prostate
PC-3 and colorectal SW-620) show ampliﬁcation only at
the MYC locus, whereas three (ovarian OVCAR-4, lung
NCI-H460 and NCI-H23) present a diffuse ampliﬁcation
in a region of >1.5Mb pairs around the MYC locus on
chromosome 8 (Supplementary Figure S6 and
Supplementary Spreadsheet S3). Although to our know-
ledge the MYC ampliﬁcation is known for HL-60, it had
not been documented for the ﬁve other cell lines.
TOP1MT transcriptional regulation is related to MYC
expression
Analysis of the TOP1MT gene with TRANSFAC [a
database for prevision of transcription factors binding
sites (http://www.biobase-international.com/index.php?
id=transfac)] revealed two canonical E-box motifs (CA
CGTG) at position 1598 and 2227 of the TOP1MT
gene sequence, located within TOP1MT’s ﬁrst intron
(Figure 5A). Moreover, three non-canonical binding
sites are located in the 3000 bps upstream of the
TOP1MT start nucleotide and eight are located in the
ﬁrst intron (Figure 5A).
To further assess the relationship between TOP1MT
and MYC expression, we tested whether TOP1MT expres-
sion could be modulated by MYC expression in cells
where MYC was either induced or downregulated. MYC
overexpression was tested by doxycycline supplementation
6626 Nucleic Acids Research, 2011,Vol.39, No. 15Figure 3. Unsupervised hierarchical clustering of MNEGs divides them into functionally meaningful groups. (A) Dendrogram of the NCI-60 based
on Euclidean distance of gene expressions, clustered according to the average linkage method. The colored bar ﬂanking the cell names indicates
tissues of origin, as shown underneath. (B) Cluster image map (CIM) of MNEGs in the NCI-60. One thousand six hundred and eighteen probes were
used to generate the CIM. Unsupervised clustering was based on Euclidean distance and generated according to the average linkage method.
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(continued)of MYC-inducible MCF7-PJMMR1 cells (41). Figure 5B
shows that MYC overexpression produced a 50% increase
in TOP1MT expression (P<0.01), as assessed by RT–
PCR 48h after doxycycline supplementation. Under
these conditions, MYC overexpression also induced a
2-fold increase in TFAM expression (P<0.001).
Conversely, a signiﬁcant reduction in TOP1MT
expression was observed after MYC silencing by siRNA
interference in MCF7 cells (Figure 5C). Under these con-
ditions, MYC inactivation also reduced TFAM expres-
sion, which is consistent with results obtained in rat cells
chronically deprived of MYC (28). Altogether, these
results provide molecular genetic evidence for the regula-
tion of TOP1MT by MYC.
Figure 3. Continued
Left: colored bar representing the tissues of origin. Top: gene dendrogram and functions associated with the four main clusters generated by
CIMminer (http://discover.nci.nih.gov/cimminer). Functions associated with individual clusters were obtained using MetaCore from GeneGo Inc.
Bottom: the position in the CIM of selected genes from Figure 2B is shown, with colors corresponding to the associated functional groups (see
underneath). Our CIMminer tool was used to generate the dendrogram and the cluster image map. (C) CIM of MNEG pair-wise correlations
clustered according to Euclidean distance and the average linkage method. To generate the CIM, a matrix of Pearson’s correlation coefﬁcients
between the available 1618 probes was generated. Highly positive correlations are in red, whereas negative correlations are in turquoise (see scale).
Yellow boxes numbered from 1 to 4 highlight visually coherent clusters of positively correlated genes. Bottom: selected genes from Figure 2B are
represented with colors according to their functional groups. Other genes of interest are shown below their clusters. Right: functions associated with
each cluster, obtained by analyzing the clustered genes using MetaCore from GeneGo Inc.
Figure 4. Co-expression of TOP1MT and MYC transcripts across the NCI-60. TOP1MT and MYC transcript z-score intensities across the NCI-60.
Each bar represent a transcript z-score for a given cancer cell line. Individual cell names and tissues are reported in the boxes besides the ﬁgure. The
Pearson’s correlation coefﬁcient for the NCI-60 values between TOP1MT and MYC is represented above the squared brackets. Stars on the side of
the individual bars in the MYC bar-chart highlight those cell lines with evident MYC copy number variations as assessed by aCGH.
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By performing genome-wide cancer cell line analysis of
gene expression microarrays in the extensively
characterized NCI-60 panel (33,34,36), we demonstrate
the highly coordinated expression of mitochondrial topo-
isomerase TOP1MT with the nuclear genes that drive the
mitochondrial machinery (MNEGs) including the genes
that encode the essential elements of the mitochondrial
DNA regulation and scaffolding structures known as
nucleoids (8,13,14). Then we demonstrate that MYC is
co-expressed with TOP1MT and other MNEGs, and
show that altering MYC transcription inﬂuences
TOP1MT levels. Our results provide the ﬁrst evidence
that TOP1MT is positively regulated by MYC, and
extend prior reports indicating the relevance of MYC for
mitochondrial regulation (23–30).
TOP1MT is the only mitochondrial enzyme with topo-
isomerase type IB activity in vertebrates (9,10,15,16).
TOP1MT has recently been shown to undergo alternative
splicing (15) but its gene regulation and system biol-
ogy have remained unknown. Here, we studied
TOP1MT expression characteristics using the NCI-60
panel whose high quality gene expression data (34,36,42)
enabled us to deﬁne a genomic signature for TOP1MT
that was then used to identify the genome-wide relation-
ships of TOP1MT with the other nuclear genes. Our
data indicate that TOP1MT is overall highly ex-
pressed, although with a wide ( 8-fold) range across the
NCI-60. Clustering based on MNEG expression
(including TOP1MT) separated cell lines according to
their tissues of origin, further implying cancer tissue spe-
ciﬁcity in the mitochondrial transcriptome. The negative
Figure 5. Regulation of TOP1MT expression by MYC.( A) Schematic representation of putative MYC binding sites in the TOP1MT promoter and
ﬁrst intron. The putative binding site sequences are listed (canonical and non-canonical E-boxes shaded in gray, with canonical E-boxes highlighted
in bold with arrows; data from the TRANSFAC database). (B) MYC, TOP1MT and TFAM mRNA induction in MCF7-PJMMR1 cells after
supplementation of doxycycline (1mg/ml) for 48h. mRNA expression was normalized to b2-microglobulin expression, and is plotted relative to
baseline. Experiments performed in triplicate are shown as mean±SD. (C) Effect of MYC down-regulation on TOP1MT and TFAM
transcription. MCF7 cells were transfected with siRNA targeting MYC or a non-silencing siRNA for 72h (see western blot at left). Expression
of MYC, TOP1MT and TFAM mRNA is normalized to b2-microglobulin mRNA expression. Experiments performed in triplicate are shown as
mean±SD. **P<0.01.***P<0.001 (t-test, two-tailed).
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sibility of a genetic complementation in TOP1MT-deﬁ-
cient cell lines by TOP2A in mitochondria (our
unpublished data).
The tissue-speciﬁc differences in TOP1MT expression
observed in the NCI-60 might not necessarily be a
simple reﬂection of what has been described in healthy
specimens, as reported by eNorthern blot by NCBI’s
Unigene dataset [see Ref. (50) http://www.genecards.org/
info.shtml#exp and Supplementary Figure S7]. TOP1MT
transcript abundance may reﬂect mitochondrial metabolic
activity in cancer cells. Comparing our observation with
the Unigene data set, it appears that, by eNorthern blot
analysis, bone marrow-derived neoplastic tissues have
higher TOP1MT levels compared to their healthy coun-
terparts, whereas gliomas are among the lowest TOP1MT
expressers among all the cancer tissues analyzed. The rele-
vance of such differences remains under study as we are
characterizing the phenotype of Top1mt knockout cells
and mice (our ongoing studies).
Genome-wide correlations across the NCI-60 demon-
strate that TOP1MT is signiﬁcantly co-expressed with a
great proportion of the neoplastic mitochondrial tran-
scriptome, and especially with genes participating in the
mitochondrial structures of nucleoids. Since these nucleo-
protein complexes contribute to mtDNA scaffolding, or-
ganization and metabolism (8,13,14), their co-expression
together with TOP1MT in cancer cells highlights an in-
trinsic order in the regulation of the mitochondrial ma-
chinery. Speciﬁcally, these ﬁndings may imply the
importance of TOP1MT in both structural maintenance
of these organelles, and in the proper progression of their
metabolic regulation and replication inside eukaryotic
cells.
Clustering MNEG expressions across the NCI-60
revealed a high level of transcriptional co-regulation
among the mitochondrial genes encoded in the nucleus.
We ﬁnd that the nuclear-encoded mitochondrial genes
tend to cluster according to speciﬁc pathways and func-
tions, with oxidative phosphorylation, ubiquinone
metabolism, mtDNA metabolism and scaffolding being
represented by highly expressed genes. In contrast,
amino acid, nitrogen and fatty acid metabolism genes gen-
erally show low transcriptional intensities. It is tempting
to speculate that such differences in gene expression may
reﬂect the adaptation process of cell lines to in vitro culture
conditions and media (including relatively high O2 con-
centration, media rich in amino acids and other nutrients).
TOP1MT itself, with its likely role in mitochondrial me-
tabolism and cell proliferation, may be a major factor of
the metabolic programs selected by some tumor tissues for
energy production. Of note, it is intriguing that the small
group of pro-apoptotic genes observed in Cluster 3 of
Figure 3C seems to behave independently, being inversely
correlated with most other MNEGs. This might be the
object of future studies investigating the ways by which
cancer cell lines down-regulate pro-apoptotic genes.
Our ﬁnding that, among more than 2700
non-mitochondrial genes that are highly positively
correlated with TOP1MT (P<0.01), MYC is at the very
top, led us to analyze in further detail the relationship
between MYC and TOP1MT. Validation of the signiﬁ-
cance of MYC is further suggested by the fact that two
MYC transcription targets AP4 (TFAP4) and TAF4B
(41,49) rank ﬁrst and second, next to MYC in the list of
genes highly correlated with TOP1MT. Moreover, add-
itional analysis of the publicly available Wooster micro-
array array data repository (see Supplementary Figure S5)
also shows high correlation between TOP1MT and MYC
in a completely unrelated dataset of more than 300 cancer
cell lines of different histotypes, adding strength to our
observation connecting MYC and TOP1MT.
Chromatin immunoprecipitation analyses have
demonstrated the binding of MYC to several MNEG pro-
moters (28,51). Likewise, the relevance of MYC in
inﬂuencing the mitochondrial transcriptome has been es-
tablished by several studies conducted with gene expres-
sion microarrays on human ﬁbroblasts (23), rat cells (27),
endothelial cells (24) and drosophila models (52). The
abundance of MNEG transcripts was also found increased
after MYC induction in human B-cell lines, MYC-indu-
cible engineered murine ﬁbroblasts and primary hepato-
cytes derived from conditional knockout mice (28,30,51).
Accordingly, our analysis demonstrates that MYC is
co-expressed with a vast proportion of MNEGs in the
NCI-60. Our comparative genomic approach is different
from what previously published using limited number of
cell lines in individual experiments. Here, we studied the
convergence of gene expressions of a wide range of cell
lines, analyzed in their basal condition. To our knowledge,
no other study has taken into consideration together a
relatively large number of cancer cell lines, observing by
means of correlation the co-regulation of MYC with the
mitochondrial transcriptome. We are aware that a limita-
tion of our analysis lies in the absence of genome-wide
dynamic experiments, which, given the complexity of the
multicell line system used, are not feasible. However, there
is a solid experimental literature to imply that the exten-
sive correlations observed in the NCI-60 between MYC
and MNEGs are not accidental, but rather suggest the
relevance of MYC in controlling mitochondrial biogenesis
in cancer (23–30), thereby coordinating increased cell
division with enhanced oxidative phosphorylation to
provide sufﬁcient energy and anabolic substrates for
tumor cell proliferation.
We provide evidence that MYC regulates the transcrip-
tion of TOP1MT by showing the presence of multiple
MYC binding sites (E-boxes) in the TOP1MT promoter
and ﬁrst intron, and by showing that after MYC induction
or silencing, the expression of TOP1MT transcript varies
accordingly. This result is in line with a recent study by
Morrish et al. (30) using a rat ﬁbroblast model of isogenic
myc
( / ), myc
(+/ ), myc
(+/+) and myc
( / ) cell lines with an
inducible c-myc transgene (mycER), showing that MYC
coordinates the regulation of mitochondrial genes
(TOP1MT and TFAM were included in a
Supplementary Table in that study). Thus, the regulation
of TOP1MT transcription by MYC is consistent with the
regulation of the other MNEGs by MYC.
Finally, although both MYC and TOP1MT are on
human chromosome 8 ( 15.6Mb pairs apart), ampliﬁca-
tions in the MYC locus did not extend to the TOP1MT
6630 Nucleic Acids Research, 2011,Vol.39, No. 15locus in any of the cell lines analyzed by aCGH (see
Supplementary Spreadsheets S3 and S4, and
Supplementary Figure S6). This rules out the possibility
of an effect of common DNA copy number alterations on
MYC and TOP1MT gene transcription in our analysis.
In conclusion, our study demonstrates, in base-line con-
ditions and without any system-altering methodology, the
co-regulation of the MNEGs including TOP1MT in a
panel of 60 cancer cells (the NCI-60). It implicates MYC
as a master regulator of TOP1MT and mtDNA enzymes.
Moreover, our ﬁndings imply that the mitochondrial tran-
scriptome of cancer cells acts as a highly coordinated
ensemble of genes under the control of master regulators
like MYC, with cell and cancer tissue speciﬁcities. The
remarkable coordination of the MNEGs is consistent
with the possibility that, on the one hand, common mech-
anisms act on eukaryotic cells to ensure proper energy
production, and, on the other hand, exploiting cancer
tissue differences in mitochondrial metabolism may be
used to target energy production pathways in a more se-
lective way than previously imagined.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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